Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3764321 | 1.00 | ACHE (0.42) | ACHEPRMT6SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL3769564 | 0.91 | HDAC3 (0.45) | ALDH1A1TDP1KDM4E | |
| SCHEMBL3769562 | 0.91 | HDAC3 (0.45) | ALDH1A1TDP1KDM4E | |
| SCHEMBL3775504 | 0.80 | HTT (0.44) | SMN1; SMN2ALDH1A1CYP2C9GAA | |
| SCHEMBL3775498 | 0.80 | HTT (0.44) | SMN1; SMN2ALDH1A1CYP2C9GAA | |
| SCHEMBL3782468 | 0.78 | HDAC4 (0.38) | ACHESMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3782469 | 0.78 | HDAC4 (0.38) | ACHESMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3764328 | 0.76 | RELA (0.42) | TDP1 | |
| SCHEMBL3771665 | 0.76 | CCNB2 (0.45) | — | |
| SCHEMBL3771661 | 0.76 | CCNB2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317630-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317630-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GRIK5, HRH2 | ACHE 319/4885PRMT6 2737/4885SMN1; SMN2 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.